A higher 600 mg daily dose of FT-4202, a potential disease-modifying oral treatment…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
The opioid crisis, along with the stigma of suspected drug use, and racial bias all contribute to make…
A new consortium has been launched by the Critical Path Institute (C-Path) to support the…
The Scottish Medicines Consortium (SMC) has approved the use of Xromi (hydroxycarbamide),…
Pediatric patients with sickle cell disease complicated by acute kidney injury (AKI)…